b-Adrenergic receptors in mononuclear leukocyte preparations were assessed with (−)[ 3 H]-dihydroalprenolol binding studies during the infusion of adrenergic agonists into normal human subjects. During the infusion of isoproterenol into seven subjects, mean (±SE) (−)
increased from 25±3 fmol/mg protein to 47±8 fmol/mg protein (P < 0.02) at 0.5 h and 40±3 fmol/mg protein (P < 0.01) at 1 h and decreased to 12±1 fmol/mg protein (P < 0.01) at 4-6 h. During the infusion of epinephrine into three subjects, mean (-)pH]dihydroalprenolol binding increased from 32±3 to 63±3 fmol/mg protein (P < 0.01) at 0.5-1 h. By Scatchard plot analysis, these changes were attributable to changes in the number of available binding sites rather than changes in binding affinity. The observed changes in the number of (-)pH]dihydroalprenolol binding sites were not paralleled by changes in total mononuclear cell counts or in T lymphocyte, B lymphocyte, and monocyte distributions. Thus, we conclude that adrenergic agonists modulate the number of available f8-adrenergic receptors on circulating mononuclear cells in a biphasic manner, with an early increment and a late decrement, in man. Further, the finding that the increase in pulse rate in response to a "pulse" infusion of isoproterenol was significantly greater after 0.5-1 h of agonist infusion suggests that the observed early agonist-induced increment in f3-adrenergic receptor number on circulating cells is paralleled by increments in extra-vascular, -adrenergic receptor sensitivity.
INTRODUCTION
It has become increasingly apparent that a variety of hormones and neurotransmitters modulate their own 836 biologic expression through modification of the activity of their cellular receptors (1) . The most commonly recognized pattern is that of a reciprocal relationship between ambient agonist concentration and receptor function as exemplified by insulin and its receptors; thus, high ambient insulin levels are associated with decreased receptor binding of insulin, whereas low ambient insulin levels are associated with increased receptor binding of insulin. Examples of a direct relationship between ambient agonist concentration and receptor function have been, however, recognized. For example, steroid hormones have been shown to induce their intracellular receptors (2) and prolactin has been reported to increase its plasma membrane receptor (3) .
The effects of the catecholamines on their receptors have been extensively studied in animals. In general, measures that result in a relatively chronic decrease in catecholamine release result in increased adrenergic receptors and enhanced sensitivity to the biologic effects of the catecholamines (supersensitization), whereas measures that result in a relatively chronic increase in ambient catecholamine levels result in decreased adrenergic receptors and reduced sensitivity to the biologic effects of the catecholamines (desensitization) (4) . As an example of the latter, Lefkowitz and co-workers (5, 6) have shown that exposure of frog erythrocytes to the ,3-adrenergic agonist isoproterenol in vitro, results in a decrease in 8-adrenergic receptor number and in adenylate cyclase responsiveness and that similar changes follow the in vivo administration of isoproterenol to the frog. This phenomenon was reversible and was not a function of a change in receptor turnover. Similarly, isoproterenol administration to rats has been shown to result in a decrease in 8-adrenergic receptor number in pineal plasma membranes (7) . With the development of techniques for the assessment of fadrenergic receptors on circulating leukocytes (8, 9) , this observation has been extended to man in that ingestion of the f-adrenergic agonist terbutaline for as little as 3 d by normal subjects and patients with asthma was found to result in a reduction in the number of polymorphonuclear leukocyte ,-adrenergic receptors (10) . In contrast, intravenous infusion of the adrenergic agonists isoproterenol (11) and epinephrine (12) was not found to alter leukocyte /8-adrenergic receptors. However, in the studies reported here we find a biphasic change in mononuclear cell f8-adrenergic receptor number, with an early increase and a later decrease, during the intravenous infusion of the ,8-adrenergic agonist isoproterenol, and a similar early increase in mononuclear cell f8-adrenergic receptor number during the infusion of the mixed adrenergic agonist epinephrine, in normal human subjects. METHODS Adrenergic agonist infusions. 13 normal young men consented to adrenergic agonist infusions performed, after an overnight fast, in the outpatient facilities of the Washington University Clinical Research Center. All subjects were free of recognizable cardiac disease, were normotensive, and had normal electrocardiograms. The electrocardiogram was continuously monitored throughout all agonist infusions. Agonists were diluted in saline containing ascorbic acid, 0.5 mg/ml, and infused for 1-6 h with a Harvard infusion pump (Harvard Apparatus Co., Inc., South Natick, Mass.). The agonists infused were isoproterenol (2.0 ,mg/min, n = 5; 1.0 gg/min, n = 4), epinephrine (5.0 ug/min, n = 3), and norepinephrine (5.0 jig/min, n = 1).
In four subjects infused with isoproterenol (1.0 ,ug/min) and one subject infused with epinephrine (5.0 ,tg/min), the increment in heart rate after a 10-min "pulse" infusion of isoproterenol (1.0 ,ug/min) was measured 1 h before agonist infusion and again after 0.5-1 h of agonist infusion while the agonist infusion was continued. In three of these subjects, blood samples for binding studies were drawn before the isoproterenol pulses. Preliminary studies demonstrated that such isoproterenol pulses alone did not alter heart rate responses or binding results determined 1 h later.
Blood samples for the binding studies described below were drawn before and at various time points during agonist infusions with the exception of two 1.0-,ug/min isoproterenol infusions during which such samples were not drawn.
Mononuclear cell preparation. Mononuclear cells were separated from heparinized whole blood (80-100 ml) by the method of Boyum (13 (8) . 300-400 ,ug ofmononuclear cell protein (14) , derived from -6 x 106 cells, were incubated with 0.1-10.0 nM (-)[H]dihydroalprenolol and incubation buffer containing 1 ,uM phentolamine (Ciba Pharmaceuticals Co., Div. Ciba-Geigy, Summit, N. J.) in a total incubation volume of 150 gl for 20 min at 37°C. Incubations were terminated by dilution with 2 ml of cold (4°C) incubation buffer followed by rapid filtration through Whatman GF/C glass fiber filters (Whatman, Inc., Clifton, N. J.). The filters were then washed with 12 ml of cold buffer and, after appropriate preparation, counted in a liquid scintillation spectrometer. Specific binding of( -) PH]dihydroalprenolol was considered to be that displaced by 1.0 ,M (-)propranolol and was -80% of total binding under the conditions used. Phentolamine, in the concentration used (1.0 gM), decreased nonspecific, but not specific binding. Specific binding increased linearly with increasing mononuclear leukocyte protein (85-500 MLg), the latter determined by the method of Lowry et al. (14) .
Preliminary studies established that the mononuclear cell preparation contained binding sites characteristic of a f3-adrenergic receptor. Binding of(-)PH]dihydroalprenolol was saturable, rapid (with half-time of association and dissociation of <4 min), and of high affinity (Kd, 0.1-2.0 nM). The preparation exhibited the appropriate agonist potency sequence for displacement (isoproterenol > epinephrine > norepinephrine) and stereospecificity for displacement [(-)propranolol > (+)propranolol; (-)isoproterenol > (+)isoproterenol]. Scatchard plots were linear. The preparation was susceptible to desensitization (with a decrease in the number ofbinding sites but no change in binding affinity) during incubation with 1.0 ,uM isoproterenol for 2 h in vitro.
Lymphocyte subpopulations. T lymphocytes and B lymphocytes were separated by the method described by MacDermott et al. (15) in samples obtained during three adrenergic agonist infusions (two with isoproterenol, one with epinephrine).
Statistics. Student's t tests for paired and unpaired data were used.
RESULTS
A biphasic change, an initial increase with a subsequent decrease, in (-) [H]dihydroalprenolol binding to mononuclear cell preparations obtained before and during the infusion of isoproterenol for 4-6 h in seven normal human subjects is illustrated in Fig. 1. (-) [3H]dihydroalprenolol binding increased from a mean (+SE) of 25±3 fmol/mg protein before infusion to 47±8 finol/mg protein (P < 0.02) at 0.5 h and 40+3 fmol/mg protein (P < 0.01) at 1 hand decreased to 12±1 finol/mg protein (P < 0.01) at 4-6 h. Similar increments in (-)[3H]dihydroalprenolol binding, from 32±3 to 63±3 finol/mg protein (P < 0.01), during the infusion of epinephrine over 1 h are also shown in Fig. 1. (-) [3H]dihydroalprenolol binding did not change (20 finol/mg protein) during a single 1-h infusion of norepinephrine (Inot shown). By Scatchard plot analysis, these chainges in (-) [3H]dihydroalprenolol binding were attributable to changes in the number, rather than the affinity, of binding sites as illustrated by the data from an isoproterenol infusion shown in Fig. 2 and the data from an epinephrine infusion shown in Fig. 3 .
As shown in Table I [(-) [3H]-DHA] binding to mononuclear cell preparations, obtained before and at the indicated times, during the infusion of isoproterenol (I, left) in seven subjects and the infusion of epinephrine (E, right) in three subjects. The numbers at the base of each column indicate the number of observations at the corresponding duration of agonist infusion. (*) P < 0.05, (**) P < 0.02, and (***) P < 0.01. lymphocytes, B lymphocytes, or monocytes. Total leukocyte and mononuclear cell counts increased during epinephrine but not isoproterenol infusions.
In five subjects pulsed with isoproterenol for 10 min before and after 0.5 or 1 h of isoproterenol (ni = 4) or epinephrine infusions, the increment in pulse rate rose from 9±2 beats/min before agonist infusion to 17±4 beats/min (P < 0.05) during agonist infusion. Samples for binding studies were obtained in three of these subjects. As shown in Fig. 4 (11) found no significant change in the number of ,3-adrenergic receptors in moinonuclear cells during the infusioin of isoproterenol. One consistent difference between these studies and this studv is the use of considerably larger doses of isoproterenol in the former studies. Shamoon et al. (12) observedl no change in mononuclear cell /3-adrenergic receptors during 4-h infusions of epinephrine, in doses comparable with those we used, into humans although the time points examined by these investigators are not clear.
Similarly, an agonist-induced increase in 3adrenergic receptors has not been observed in the vast majority of in vitro studies. There (20) and that S-adenosyl-L-methionine stimulated phosphatidylcholine synthesis resulted in a linear increase in the number of available ,B-adrenergic receptors over 60 min (21 cholamines are cleared through f-adrenergic mechanisms (22) , agonist-induced enhancement of 8-adrenergic receptor sensitivity may well explain the recent observation that the catecholamines accelerate their own metabolic clearance (23) .
